US Stock Market Movement: Oruka Therapeutics surges on October 26 driven by ORKA-001 Phase II data and psoriasis antibody

Oruka Therapeutics October 26 Surge Interpretation

Keywords: ORKA-001 Phase II data, psoriasis antibody

1. On October 26, 2026, the company announced the 16-week results of the EVERLAST-B Phase IIb trial: The high-dose group of ORKA-001 (600 mg) had a PASI 100 response rate of 61% and a PASI 90 response rate of 86%, while the placebo group had a PASI 100 response rate of 0%. The trial enrolled a total of 187 patients with moderate to severe plaque psoriasis.

2. On October 26, 2026, the company disclosed that the safety and tolerability profile of ORKA-001 aligns with the characteristics of IL-23p19 class drugs, and plans to launch a Phase III trial for moderate to severe psoriasis in the first half of 2027 after regulatory communication.

(Disclaimer: This content is generated by AI technology based on publicly available information for summary purposes only and does not constitute investment advice.)